Phase II results with SIBIA's altinicline

SIBIA Neurosciences has revealed data from two Phase II clinicaltrials of SIB-1598Y (altinicline) in Parkinson's disease patients. The first study evaluated multiple doses of SIB-1598Y over a four-week period to determine the efficacy of the compound in treating the motor and cognitive symptoms associated with early-stage disease. The company says that SIB-1598Y was well-tolerated but did not demonstrate a significant improvement versus placebo. The second crossover study examined acute motor and cognitive performance over an eight-hour period. Later-stage Parkinson's patients were administered placebo or one of three doses of SIB-1598Y in combination with half their individually-effective dose of levodopa. Again, SIB-1598Y was found not to be significantly different to placebo in the global analysis, although a trend to significance was noted.